 |
|
Hyperhomocysteinemia and Atherosclerotic Vascular Disease
Pathophysiology, Screening, and Treatment
James H. Stein, MD;
Patrick E. McBride, MD, MPH
Arch Intern Med. 1998;158:1301-1306.
ABSTRACT
| |
Hyperhomocysteinemia has recently been identified as an important risk factor for atherosclerotic vascular disease. This article reviews homocysteine metabolism, causes of hyperhomocysteinemia, the pathophysiological findings of this disorder, and epidemiological studies of homocysteine and vascular disease. Screening for hyperhomocysteinemia should be considered for patients at high risk for vascular disease or abnormalities of homocysteine metabolism. For primary prevention of vascular disease, treatment of patients with homocysteine levels of 14 µmol/L or higher should be considered. For secondary prevention, treatment of patients with homocysteine levels of 11 µmol/L or higher should be considered. Treatment is most conveniently administered as a folic acid supplement (400-1000 µg) and a high-potency multivitamin that contains at least 400 µg of folate. Higher doses of folic acid and cyanocobalamin supplements may be required in some patients. Until prospective clinical trial data become available, these conservative recommendations provide a safe, effective, and evidence-based approach to the diagnosis, evaluation, and management of patients with hyperhomocysteinemia.
INTRODUCTION
The observation that up to 19% of patients in large clinical trials of low-density lipoprotein cholesterol–lowering therapy experienced adverse cardiovascular events, despite this powerful intervention, has intensified the search for new, nonlipid risk factors for atherosclerotic vascular disease (ASVD).1-4 Hyperhomocysteinemia, a metabolic abnormality that can be detected in up to 30% of patients with coronary artery disease (CAD) and 42% of patients with cerebrovascular disease, recently has been identified as an important risk factor for ASVD.4-6 The purpose of this article is to provide an evidence-based approach to the diagnosis and management of patients with hyperhomocysteinemia. In this context, homocysteine metabolism, the causes of hyperhomocysteinemia, and the pathophysiological findings of this disorder are reviewed, as are the epidemiological studies that have implicated hyperhomocysteinemia as a predictor of increased risk of ASVD. On the basis of these discussions, practical recommendations for the screening and treatment of patients with this disorder are provided.
HOMOCYSTEINE METABOLISM
Homocysteine is an amino acid intermediate in the metabolism of methionine, an essential amino acid found in both animal and plant proteins (Figure 1). The recommended daily allowance of methionine is 0.9 g; however, the average American diet contains approximately 2 g/d of methionine, the excess of which is converted via enzymatic transmethylation to homocysteine.6 Homocysteine is converted to cystathionine via a transsulfuration pathway that is dependent on the vitamin B6–dependent enzyme cystathionine  -synthase.6-8 Cystathionine is then converted into cysteine, which is eventually degraded and excreted in the urine. Homocysteine also may be recycled back into methionine by either of 2 remethylation pathways, the most important of which involves the vitamin B12–dependent enzyme methionine synthase and its cosubstrate, 5-methyltetrahydrofolate.6-8 The other remethylation pathway is independent of vitamin B12 and folate but uses betaine as a cofactor.6-8
|
|
|
|
Figure 1. Homocysteine metabolism. SAM indicates S-adenosyl methionine; SAH, S-adenosyl homocysteine; CBS, cystathionine -synthase; MS, methionine synthase; 5 MTHF, 5-methyltetrahydrofolate; MTHFR, 5-methyltetrahydrofolate reductase; NADPH, nictotinamide adenine dinucleotide phosphate; and TH Folate, tetrahydrofolate.
|
|
|
CAUSES OF HYPERHOMOCYSTEINEMIA
Hyperhomocysteinemia may result from abnormalities in the function of any of the enzymes involved in homocysteine metabolism or from deficiencies of enzyme cofactors or cosubstrates (ie, folate, vitamin B6, or vitamin B12) (Table 1).
|
|
|
|
Table 1. Causes of Hyperhomocysteinemia
|
|
|
Diminished activity of methionine synthase or 5-methyltetrahydrofolate reductase because of genetic abnormalities, vitamin deficiencies, or medication use may cause hyperhomocysteinemia.6, 8-11 Indeed, the most common form of genetic hyperhomocysteinemia results from production of a thermolabile variant of 5-methyltetrahydrofolate reductase with decreased activity.12 Homozygosity for this mutant enzyme is present in 9% to 17% of the population, and heterozygosity can be detected in 30% to 41% of the general population.12-16 Homozygous cystathionine -synthase deficiency causes homocystinuria, a rare disorder characterized by mental retardation, arterial and venous thrombosis, and premature atherosclerosis. Affected individuals may have plasma total homocysteine (tHcy) levels as high as 300 to 500 µmol/L.6, 8-9 Although homocystinuria is a rare disorder, heterozygous deficiency of this enzyme is prevalent in the United States at a frequency of 1 per 300 and may cause moderately elevated tHcy levels.9
Because these vitamins function as cofactors or cosubstrates in the enzymatic reactions involved in homocysteine metabolism, severe hyperhomocysteinemia may be detected in patients with low levels of folate or vitamin B12, even when serum levels of these vitamins are in the low-normal range.17-23 The association between vitamin B6 deficiency and hyperhomocysteinemia is less clear; however, vitamin B6 and homocysteine levels seem to be inversely related.17, 22, 24
Clinically, tHcy levels tend to increase with older age and tobacco use.25-27 Men tend to have higher tHcy levels than women, and tHcy levels tend to be elevated in individuals with renal dysfunction, unexplained deep venous thrombosis, systemic lupus erythematosus, malignant neoplasms, psoriasis, and solid organ transplantation.6, 25-36 After a myocardial infarction or a cerebrovascular accident, tHcy levels are subject to an acute-phase response, characterized by an initial reduction of approximately 25%, followed by a convalescent increase of approximately 20% to 22%, that can interfere with interpretation of laboratory values obtained up to 3 months after these events.7, 37-38 The effect of surgery and other systemic illnesses on tHcy levels has not been well characterized. Finally, several commonly used medications, including methotrexate, nitrous oxide, phenytoin, carbamazepine, nicotinic acid, colestipol, and thiazide diuretics, increase tHcy levels.6, 28, 34, 39
HYPERHOMOCYSTEINEMIA AND ATHEROSCLEROSIS
The vascular and hematologic abnormalities associated with hyperhomocysteinemia lead to a proatherogenic and prothrombotic metabolic milieu (Table 2).6, 8 These abnormalities include (1) endothelial cell injury, the initial event in the development of atherosclerosis, manifested as impaired endothelium-dependent vasodilation and impaired endogenous tissue-type plasminogen activator activity; (2) increased platelet aggregation, related to increased synthesis of thromboxane A2 and decreased synthesis of prostacyclin; and (3) abnormalities of the clotting cascade, such as activation of factors V, X, and XII, and inhibition of natural anticoagulants, such as antithrombin III and factor C.6, 8, 40 Homocysteine promotes the binding of lipoprotein(a) to fibrin and the growth of smooth muscle cells, and tHcy levels correlate with levels of fibrinogen, an independent risk factor for ASVD.41-44
|
|
|
|
Table 2. Pathophysiological Findings of Hyperhomocysteinemia
|
|
|
HYPERHOMOCYSTEINEMIA: EPIDEMIOLOGICAL FINDINGS AND ASVD RISK
Several studies have demonstrated strong associations between hyperhomocysteinemia and CAD (especially premature CAD),5, 7, 17, 23, 45-50 cerebrovascular disease,5, 45, 50-53 and peripheral arterial vascular disease.5, 45, 50, 53
One of the earliest studies that related hyperhomocysteinemia and ASVD was conducted in Dublin, Ireland.5 Hyperhomocysteinemia, defined as a tHcy level greater than the high threshold level of 24 mmol/L, was more predictive of ASVD than any other risk factor.5 After adjustment for hypercholesterolemia, hypertension, and tobacco abuse, hyperhomocysteinemia was associated with an overall odds ratio (OR; lower limits of 95% confidence limits) for ASVD of 1.39.
In the Physicians' Health Study, 14916 male physicians without known ASVD were followed up prospectively for 5 years.46 Plasma tHcy levels were higher in the 271 patients with myocardial infarction than in healthy controls, and the adjusted risk for the highest fifth percentile vs the bottom 90th percentile of tHcy levels was 3.1.46 This finding was verified by a study of 21826 patients in Tromso, Norway, in which the relative risk of CAD increased by 1.32 for each 4-µmol/L increase in tHcy levels.47 The increased risk associated with increasing tHcy levels was observed in both males (10983 patients) and females (10863 patients) and across a wide range of ages (12-61 years) and tHcy values (3.5-35.0 µmol/L).47 Furthermore, no threshold effect was observed.47
In the British Regional Heart Study,52 5661 middle-aged men from the United Kingdom were followed up prospectively for up to 13 years. Plasma tHcy levels were higher in the 109 patients with stroke than in controls, and the adjusted relative risk of cerebrovascular disease for the highest quartile of tHcy levels was 2.8.52 These data were verified by the Framingham Heart Study of 1041 patients, in which the OR of having significant carotid artery stenosis was 2.0 for patients with tHcy levels greater than 14.4 µmol/L.51 A critical observation in this study was that tHcy elevations within the "normal" range (11.4-14.3 µmol/L) also were associated with increased risk of cerebrovascular disease (OR=1.6).51 Furthermore, the risk of significant carotid artery stenosis was associated with decreasing folate levels.51
Recently, the European Concerted Action Project50 addressed the interaction between hyperhomocysteinemia and conventional risk factors for ASVD in a study of 750 case and 800 control patients younger than 60 years.50 The risk for ASVD in patients in the highest quintile of tHcy levels ( 12 µmol/L) relative to the lower quintiles was 2.2. The risk of increasing tHcy levels was continuous, and a 5-µmol/L increment in the tHcy level was associated with an OR for ASVD of 1.3 for men and 1.4 for women. The magnitude of increased risk of ASVD associated with hyperhomocysteinemia was greater than that associated with hypercholesterolemia (OR=1.4), less than that for hypertension (OR=3.9), and similar to that for tobacco use (2.2). For both sexes, the ASVD risk associated with hyperhomocysteinemia was multiplicative in the presence of tobacco use or hypertension.50
The association between CAD and decreasing folate levels also has been verified in several studies.7, 17, 22-23,31 Significant but less consistent and less powerful associations between CAD and low levels of vitamins B6 and B12 also have been described.7, 17, 22-24,31, 50
Regarding the CAD risk attributed to homocysteine levels, a recent meta-analysis established that a 5-µmol/L increase in the tHcy level was equivalent to an approximately 0.52-mmol/L (20-mg/dL) increase in the total cholesterol level (ie, 20% increased risk).8 The relative risk for CAD associated with increasing tHcy levels in this meta-analysis8 was lower than reported in the European Concerted Action Project in which a 5-µmol/L change was equivalent to a 2.22 mmol/L (86 mg/dL) change in cholesterol.50, 54
SCREENING FOR HYPERHOMOCYSTEINEMIA
Most clinical laboratories use high-performance liquid chromatography to measure plasma tHcy levels, although some laboratories still use older immunoassays. Although both techniques are sensitive, the newer techniques are more specific. Charges for these assays are typically $45 to $100 per measurement. Blood samples should be collected in tubes containing an anticoagulant such as EDTA and centrifuged within 30 minutes to avoid a false elevation of homocysteine levels due to its release from red blood cells. Accordingly, serum homocysteine measurements have a higher normal range. Samples may then be refrigerated or frozen for several weeks. Free homocysteine levels are not useful clinically.
The "normal" range for fasting tHcy values is approximately 5 to 15 µmol/L. The upper limit of this range, however, should be revised downward because the increased risk of atherosclerosis associated with tHcy levels in this range has been well documented.6, 8, 17, 47, 50-51 Certain patients with abnormal homocysteine metabolism may have normal fasting plasma tHcy levels and may require provocative testing (ie, methionine loading) to expose this abnormality.6, 8, 50 The methionine loading test involves oral administration of 100 mg/kg of methionine and measurement of the plasma tHcy level 6 to 8 hours later.6, 50 The European Concerted Action Project50 reported that methionine loading identified an additional 27% of cases, despite a strong correlation between baseline and postload tHcy values. The role of methionine loading in clinical practice is controversial, however, because of its excess cost and time commitment and interindividual variation in the time-to-peak tHcy response to methionine loading. Because most of the recent epidemiological studies that associate hyperhomocysteinemia with ASVD only measured fasting plasma tHcy levels, maintaining this practice seems reasonable, especially until the clinical utility and cost-effectiveness of methionine loading is established. The sensitivity of fasting plasma tHcy levels for identification of patients at risk for ASVD may be improved by using a lower criterion than that used in the European Concerted Action Project (12 µmol/L),50 especially for high-risk patients, such as those with established ASVD.
Screening for hyperhomocysteinemia (Table 3) should be considered for patients at risk for this disorder and for patients at high risk for ASVD who may benefit from homocysteine-lowering therapy (discussed below). Such patients include those with (1) ASVD without conventional risk factors; (2) premature ASVD (clinical ASVD event before age 60 years); (3) premature ASVD in a first-degree relative or ASVD risk factors associated with hyperhomocysteinemia, such as tobacco abuse and hypertension; (4) chronic renal failure; (5) unexplained deep venous thrombosis; (6) systemic lupus erythematosus; (7) severe psoriasis; (8) solid organ transplantation; and (9) prolonged use of medications associated with hyperhomocysteinemia (Table 1). Screening for hyperhomocysteinemia should be deferred until 8 to 12 weeks after any serious systemic illness, including myocardial infarction or stoke, because of the potential for spurious underestimations of baseline tHcy levels.7, 37-38
|
|
|
|
Table 3. Screening for Hyperhomocysteinemia*
|
|
|
THERAPY FOR HYPERHOMOCYSTEINEMIA
Clinical trial data regarding the potential benefits of homocysteine-lowering therapy for the prevention of ASVD are not yet available. In the European Concerted Action Project,50 however, users of multivitamins containing folic acid, pyridoxine hydrochloride, and cyanocobalamin had a significantly lower risk of all forms of ASVD than nonusers, even after adjustment for conventional risk factors (relative risk, 0.38), and at least some of this effect was attributable to lower tHcy levels. A similar observation was made in the Nurse's Health Study, where participants who used moderate doses of vitamin supplements containing folate and pyridoxine had fewer coronary events than nonusers.55
Therapy with folic acid at doses of 400 µg or more daily has been associated with a 30% to 42% decrease in tHcy levels.56-57 Doses lower than this do not result in a sustained reduction in tHcy levels.6, 56 Cyanocobalamin supplementation has been associated with a less dramatic reduction in tHcy levels of approximately 15%.56 In the absence of vitamin B6 deficiency, pyridoxine hydrochloride supplementation does not lower tHcy levels significantly.53, 56 Combination therapy with all 3 of these vitamins, administered orally or as a monthly intramuscular injection, has been associated with 15% to 72% reductions in tHcy levels.6, 22, 56, 58 It is doubtful that pyridoxine hydrochloride or cyanocobalamin supplementation has an additional homocysteine-lowering effect in addition to folic acid supplementation in patients without deficiencies of these vitamins.56 The US Food and Drug Administration recently mandated fortification of flours and cereal products with 140 µg of folic acid per 100 g. This intervention is expected to have a population effect of lowering tHcy levels by an average of approximately 3 µmol/L and may potentially prevent 17000 deaths due to ASVD each year.45, 59
The safety of folic acid supplementation has been well documented.59-60 Exacerbation of vitamin B12 deficiency has been reported rarely and only occurs with higher doses of folic acid (10 mg/d).60 Although folic acid supplementation may mask the red blood cell macrocytosis associated with vitamin B12 deficiency, the red blood cell mean corpuscular volume is an insensitive indicator of vitamin B12 deficiency, and more reliable indicators of vitamin B12 status are available, such as direct measurement of vitamin B12 and methylmalonic acid levels.60 Furthermore, folic acid supplementation does not mask the neurologic or cutaneous manifestations of vitamin B12 deficiency, exacerbate seizure disorders, interfere with effectiveness of antifolate medications, or increase the risk of cancer.60
SUMMARY OF RECOMMENDATIONS
In the absence of clinical trial evidence that treatment of hyperhomocysteinemia decreases the risk of ASVD or its clinical manifestations, therapy for this disorder is based on the strong epidemiological association between increasing tHcy levels and ASVD and on the safety and low cost of folic acid supplementation. There is also preliminary evidence that vitamin therapy may prevent progression of cerebral atherosclerosis.61 The optimal dose, combination, and route of administration of homocysteine-reducing therapies have not yet been clarified. Because of these limitations, the following recommendations (Figure 2) were formulated to provide a safe and effective strategy for addressing hyperhomocysteinemia in high-risk patients until clinical trials addressing these issues are completed.
|
|
|
|
Figure 2. Treatment of hyperhomocysteinemia. tHcy indicates total homocysteine; QD, every day.
|
|
|
For the primary prevention of ASVD, screening for hyperhomocysteinemia should be considered in patients at risk for this disorder and for patients at high risk for ASVD who may benefit from homocysteine-lowering therapy (Table 3). Special attention should be given to patients who smoke tobacco or have hypertension because of the association between tobacco use, hypertension, hyperhomocysteinemia, and premature ASVD.26, 50 Treatment of patients with tHcy levels of 14 µmol/L or higher, a level near the 95th percentile in the Framingham Heart Study and clearly associated with an increased risk of ASVD, should be considered.7, 17, 45, 50-51 For the secondary prevention of ASVD, a more aggressive approach to screening and therapy may be warranted, as manifest ASVD dramatically increases the risk of vascular death.1-2 In patients with established ASVD, consideration should be given to treating patients with tHcy levels of 11 µmol/L or higher, a level clearly associated with increased vascular events in the Framingham Heart Study and other studies but previously considered normal.7, 17, 45, 50-51
Because of the small risk that folic acid supplements may delay the diagnosis or potentiate the neurologic manifestations of vitamin B12 deficiency, which is relatively common in older patients, we conservatively recommend measurement of serum vitamin B12 levels in all patients with hyperhomocysteinemia, as defined by the clinical settings described above.58-60 If vitamin B12 deficiency is identified it should be evaluated, and cyanocobalamin supplementation may lower tHcy levels to an acceptable level.
If hyperhomocysteinemia persists after vitamin B12 deficiency has been excluded or treated, and offending medications have been discontinued (if possible), folic acid supplementation may be initiated as primary therapy. This is most conveniently administered as a folic acid supplement (400-1000 µg) and a high-potency multivitamin (without iron for males and postmenopausal females) that contains at least 400 µg of folic acid and the US recommended daily allowance of pyridoxine hydrochloride and cyanocobalamin. This ensures adequate intake of pyridoxine hydrochloride and cyanocobalamin during folic acid supplementation.
Levels of tHcy should be remeasured 6 to 8 weeks after initiation of homocysteine-lowering therapy. If elevated levels persist despite therapy as described above, the dose of the folic acid supplement may be increased to 2000 µg/d, with another measurement of the tHcy level after 6 to 8 additional weeks. Higher doses of folic acid (up to 5000 µg/d) may be needed for patients with end-stage renal disease or continuing sources of folic acid loss. If hyperhomocysteinemia persists, cyanocobalamin supplementation (400 µg/d), even in the absence of overt deficiency, may be beneficial. Although it is an uncommon disorder, vitamin B6 deficiency should be considered in patients with marked hyperhomocysteinemia (tHcy level 24 µmol/L) or who are refractory to folic acid therapy.
Although estrogen replacement and penicillamine therapies have reduced tHcy levels in small studies, therapy with these medications for the sole purpose of reducing homocysteine levels cannot be recommended.28, 62 Administration of betaine, a choline derivative that functions as a cofactor in the non–vitamin B12–dependent remethylation pathway of homocysteine metabolism, effectively lowers tHcy levels in patients with homocystinuria who are unresponsive to pyridoxine hydrochloride supplementation and may prevent arterial and venous thrombotic events in these patients.63-64 Use of this orphan drug in patients with less severe hyperhomocysteinemia is not recommended because of its expense and the availability and effectiveness of the therapies described above.
These recommendations for screening and treating patients with hyperhomocysteinemia, for the purposes of preventing ASVD and its complications, may be modified when more epidemiological data and prospective clinical trial data, such as from the Heart Protection Study II, become available. Until then, these conservative recommendations provide a safe, effective, and evidence-based approach to the diagnosis, evaluation, and management of patients with hyperhomocysteinemia.
AUTHOR INFORMATION
Accepted for publication November 4, 1997.
Reprints: James H. Stein, MD, University of Wisconsin Medical School, 600 Highland Ave, H6/315 CSC, Madison, WI 53792 (e-mail: jhs{at}medicine.wisc.edu).
From the Preventive Cardiology Program, Section of Cardiology, Department of Medicine, University of Wisconsin Medical School, Madison.
REFERENCES
| |
1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
FULL TEXT
|
ISI
| PUBMED
2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
FREE FULL TEXT
3. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
FREE FULL TEXT
4. Superko HR. Beyond LDL cholesterol reduction. Circulation. 1996;94:2351-2354.
FREE FULL TEXT
5. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149-1155.
ABSTRACT
6. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996;27:517-527.
ABSTRACT
7. Verhoef P, Stampfer MJ, Buring JE, et al. Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol. 1996;143:845-859.
FREE FULL TEXT
8. Rees MM, Rodgers GM. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thromb Res. 1993;71:337-359.
FULL TEXT
|
ISI
| PUBMED
9. Robinson K, Mayer E, Jacobsen DW. Homocysteine and coronary artery disease. Cleve Clin J Med. 1994;61:438-450.
ISI
| PUBMED
10. Gallagher PM, Meleady R, Shields DC, et al. Homocysteine and risk of premature coronary heart disease: evidence for a common gene mutation. Circulation. 1996;94:2154-2158.
FREE FULL TEXT
11. Kang S-S, Wong PWK, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr. 1992;12:279-298.
FULL TEXT
|
ISI
| PUBMED
12. Kang SS, Wong PWK, Susmano A, et al. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet. 1991;48:546-551.
ISI
| PUBMED
13. Goyette P, Sumner JS, Milos R, et al. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet. 1994;7:195.
FULL TEXT
|
ISI
| PUBMED
14. Ma J, Stampfer MJ, Hennekens CH, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation. 1996;94:2410-2416.
FREE FULL TEXT
15. van Bockxmeer FM, Mamotte DS, Vasikaran CSD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation. 1997;95:21-23.
FREE FULL TEXT
16. Deloughery TG, Evans A, Sadeghi A, et al. Common mutation in methylenetetrahydrofolate reductase: correlation with homocysteine metabolism and late-onset vascular disease. Circulation. 1996;94:3074-3078.
FREE FULL TEXT
17. Robinson K, Mayer EL, Miller DP, et al. Hyperhomocysteinemia and low pyridoxal phosphate: common and independent reversible risk factors for coronary artery disease. Circulation. 1995;92:2825-2830.
FREE FULL TEXT
18. Brattström L, Israelsson B, Lindgärde F, Hultberg B. Higher total plasma homocysteine in vitamin B12 deficiency than in heterozygosity for homocystinuria due to cystathionine -synthase deficiency. Metabolism. 1988;37:175-178.
FULL TEXT
|
ISI
| PUBMED
19. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270:2693-2698.
FREE FULL TEXT
20. Kang S-S, Wong PWK, Norusis M. Homocysteinemia due to folate deficiency. Metabolism. 1987;36:458-462.
FULL TEXT
|
ISI
| PUBMED
21. Lindenbaum J, Rosenberg IH, Wilson PWF, Stabler S, Allen RH. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr. 1994;60:2-11.
FREE FULL TEXT
22. Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr. 1993;57:47-53.
FREE FULL TEXT
23. Pancharuniti N, Lewis CA, Sauberlich HE, et al. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr. 1994;59:940-948.
FREE FULL TEXT
24. Miller JW, Ribaya-Mercado JD, Russell RM, et al. Effect of vitamin B-6 deficiency on fasting plasma homocysteine concentrations. Am J Clin Nutr. 1992;55:1154-1160.
FREE FULL TEXT
25. Kang S-S, Wong PWK, Cook HY, Norusis M, Messer JV. Protein-bound homocyst(e)ine: a possible risk factor for coronary artery disease. J Clin Invest. 1986;77:1482-1486.
26. Nygård O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile: the Hordaland Homocysteine Study. JAMA. 1995;274:1526-1533.
FREE FULL TEXT
27. Glueck CJ, Shaw P, Lang JE, Tracy T, Sieve-Smith L, Wang Y. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol. 1995;75:132-136.
FULL TEXT
|
ISI
| PUBMED
28. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med. 1989;114:473-501.
ISI
| PUBMED
29. Wilcken DEL, Gupta VJ. Sulphur containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulphide. Eur J Clin Invest. 1979;9:301-307.
ISI
| PUBMED
30. Wilcken DEL, Gupta VJ, Reddy SG. Accumulation of sulphur-containing amino acids including cysteine-homocysteine in patients on maintenance haemodialysis. Clin Sci. 1980;58:427-430.
PUBMED
31. Robinson K, Gupta A, Dennis V, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation. 1996;94:2743-2748.
FREE FULL TEXT
32. Heijer MD, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334:759-762.
FREE FULL TEXT
33. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet. 1996;348:1120-1124.
FULL TEXT
|
ISI
| PUBMED
34. Refsum H, Helland S, Ueland PM. Fasting plasma homocysteine as a sensitive parameter to antifolate effect: a study on psoriasis patients receiving low-dose methotrexate treatment. Clin Pharmacol Ther. 1989;46:510-520.
ISI
| PUBMED
35. Ambrosi P, Barlatier A, Habib G, et al. Hyperhomocysteinaemia in heart transplant recipients. Eur Heart J. 1994;15:1191-1195.
FREE FULL TEXT
36. Berger PB, Jones JD, Olson LJ, et al. Increase in total plasma homocysteine concentration after cardiac transplantation. Mayo Clin Proc. 1995;70:125-131.
ABSTRACT
37. Egerton W, Silberberg J, Crooks R, Ray C, Xie L, Dudman N. Serial measures of plasma homocys-t(e)ine after acute myocardial infarction. Am J Cardiol. 1996;77:759-761.
FULL TEXT
|
ISI
| PUBMED
38. Lindgren A, Brattström L, Norrving B, Hultberg B, Andersson A, Johansson BB. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke. 1995;26:795-800.
FREE FULL TEXT
39. Garg R, Malinow R, Pettinger M, Hunninghake D. Treatment with niacin increases plasma homocys-t(e)ine levels [abstract]. Circulation. 1996;94:I-457.
40. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation. 1997;95:1119-1121.
FREE FULL TEXT
41. von Eckardstein A, Malinow MR, Upson B. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. Arterioscler Thromb. 1994;14:460-464.
FREE FULL TEXT
42. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med. 1993;118:956-963.
FREE FULL TEXT
43. Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A. 1994;91:6369-6373.
FREE FULL TEXT
44. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci U S A. 1992;89:10193-10197.
FREE FULL TEXT
45. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049-1057.
FREE FULL TEXT
46. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877-881.
FREE FULL TEXT
47. Arneson E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995;24:704-709.
FREE FULL TEXT
48. Wu LL, Wu J, Hunt SC, et al. Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. Clin Chem. 1994;40:552-561.
FREE FULL TEXT
49. Dalery K, Lussier-Cacan S, Selhub J, Davignon J, Latour Y, Genest J. Homocysteine and coronary artery disease in French Canadian subjects: relation with vitamins B12, B6, pyridoxal phosphate, and folate. Am J Cardiol. 1995;75:1107-1111.
FULL TEXT
|
ISI
| PUBMED
50. Graham I, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA. 1997;277:1775-1781.
FREE FULL TEXT
51. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995;332:286-291.
FREE FULL TEXT
52. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995;346:1395-1398.
FULL TEXT
|
ISI
| PUBMED
53. Brattström L, Israelsson B, Norrving B, et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease: effects of pyridoxine and folic acid treatment. Atherosclerosis. 1990;81:51-60.
FULL TEXT
|
ISI
| PUBMED
54. Omenn GS, Beresford SAA, Motulsky AG. Preventing coronary heart disease: B vitamins and homocysteine. Circulation. 1998;97:421-424.
FREE FULL TEXT
55. Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6from diet and supplements in relation to risk of coronary heart disease among women. JAMA. 1998;279:359-364.
FREE FULL TEXT
56. Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ, Delport R, Potgieter HC. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr. 1994;124:1927-1933.
57. Robinson K Data presented at: 69th Scientific Sessions of the American Heart Association; November 12, 1996; New Orleans, La.
58. Naurath HJ, Joosten E, Riezler R, Stabler SP, Allen RH, Lindenbaum J. Effects of vitamin B12, folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet. 1995;346:85-89.
FULL TEXT
|
ISI
| PUBMED
59. Tucker KL, Mahnken B, Wilson PWF, Jacques P, Selhub J. Folic acid fortification of the food supply: potential benefits and risks for the elderly population. JAMA. 1996;276:1879-1885.
FREE FULL TEXT
60. Campbell NRC. How safe are folic acid supplements? Arch Intern Med. 1996;156:1638-1644.
FREE FULL TEXT
61. Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyperhomocyst(e)inaemia. Lancet. 1998;351:263.
ISI
| PUBMED
62. van der Mooren MJ, Wouters MGAJ, Blom HJ, Schellekens TKAB, Rolland R. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest. 1994;24:733-736.
ISI
| PUBMED
63. Wilcken DE, Wilcken B, Dudman NP, Tyrrell PA. Homocysteinemia: the effects of betaine in the treatment of patients not responsive to pyridoxine. N Engl J Med. 1983;309:448-453.
ABSTRACT
64. Wilcken DE, Wilcken B. The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis. 1997;20:295-300.
FULL TEXT
|
ISI
| PUBMED
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Reversible nitrous oxide myelopathy and a polymorphism in the gene encoding 5,10-methylenetetrahydrofolate reductase
Lacassie et al.
Br J Anaesth 2006;96:222-225.
ABSTRACT
| FULL TEXT
Renal vein thrombosis as a presenting symptom of multiple genetic pro-coagulant defects
Wolak et al.
Nephrol Dial Transplant 2005;20:827-829.
FULL TEXT
Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus
Martinez-Berriotxoa et al.
Lupus 2004;13:927-933.
ABSTRACT
Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction
Hassan et al.
Brain 2004;127:212-219.
ABSTRACT
| FULL TEXT
Association of Plasma Homocysteine Concentration With Atherosclerotic Carotid Plaques and Lacunar Infarction
Sasaki et al.
Stroke 2002;33:1493-1496.
ABSTRACT
| FULL TEXT
Hyperhomocystinemia: A Risk Factor or a Consequence of Coronary Heart Disease?
Knekt et al.
Arch Intern Med 2001;161:1589-1594.
ABSTRACT
| FULL TEXT
Thrombophilia: genetic polymorphisms and their association with retinal vascular occlusive disease
CHAK et al.
Br J Ophthalmol 2001;85:883-886.
FULL TEXT
Oxidative Stress and Homocysteine in Coronary Artery Disease
Cavalca et al.
Clin. Chem. 2001;47:887-892.
ABSTRACT
| FULL TEXT
Hypothesis : Pulse Pressure and Human Longevity
Aviv
Hypertension 2001;37:1060-1066.
ABSTRACT
| FULL TEXT
Treatment of Atherosclerotic Disease at the Cervical Carotid Bifurcation: Current Status and Review of the Literature
Connors III et al.
Am. J. Neuroradiol. 2000;21:444-450.
FULL TEXT
Preventing Coronary Artery Disease by Lowering Cholesterol Levels: Fifty Years From Bench to Bedside
Steinberg and Gotto
JAMA 1999;282:2043-2050.
ABSTRACT
| FULL TEXT
|
